 Pirenzepine
"Pirenzepine" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An antimuscarinic agent that inhibits gastric secretion at lower doses than are required to affect gastrointestinal motility, salivary, central nervous system, cardiovascular, ocular, and urinary function. It promotes the healing of duodenal ulcers and due to its cytoprotective action is beneficial in the prevention of duodenal ulcer recurrence. It also potentiates the effect of other antiulcer agents such as CIMETIDINE and RANITIDINE. It is generally well tolerated by patients.
| Descriptor ID |
D010890
|
| MeSH Number(s) |
D03.633.100.079.080.070.750
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Pirenzepine".
Below are MeSH descriptors whose meaning is more specific than "Pirenzepine".
This graph shows the total number of publications written about "Pirenzepine" by people in this website by year, and whether "Pirenzepine" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 | | 1998 | 1 | 0 | 1 | | 1999 | 2 | 0 | 2 | | 2001 | 1 | 0 | 1 | | 2003 | 2 | 0 | 2 | | 2021 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Pirenzepine" by people in Profiles.
-
Nicklas PR, Kiefer ML, Whalen MA, Stewart MT, Mosura DE, Bennett EM, Hawley WR, McLaughlin PJ. Muscarinic M1, but not M4, receptor antagonism impairs divided attention in male rats. Pharmacol Biochem Behav. 2021 06; 205:173184.
-
Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L, Paris L. Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology. 2003 Oct; 28(10):1882-8.
-
Opolka JL, Rascati KL, Brown CM, Barner JC, Johnsrud MT, Gibson PJ. Ethnic differences in use of antipsychotic medication among Texas medicaid clients with schizophrenia. J Clin Psychiatry. 2003 Jun; 64(6):635-9.
-
Opolka JL, Rascati KL, Brown CM, Gibson PJ. Role of ethnicity in predicting antipsychotic medication adherence. Ann Pharmacother. 2003 May; 37(5):625-30.
-
Malina A, Gaskill J, McConaha C, Frank GK, LaVia M, Scholar L, Kaye WH. Olanzapine treatment of anorexia nervosa: a retrospective study. Int J Eat Disord. 2003 Mar; 33(2):234-7.
-
Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL. Olanzapine versus risperidone in the treatment of schizophrenia : a comparison of costs among Texas Medicaid recipients. Pharmacoeconomics. 2003; 21(10):683-97.
-
Ross RG, Novins D, Farley GK, Adler LE. A 1-year open-label trial of olanzapine in school-age children with schizophrenia. J Child Adolesc Psychopharmacol. 2003; 13(3):301-9.
-
Hutchison KE, Swift R, Rohsenow DJ, Monti PM, Davidson D, Almeida A. Olanzapine reduces urge to drink after drinking cues and a priming dose of alcohol. Psychopharmacology (Berl). 2001 Apr; 155(1):27-34.
-
Weiss EL, Potenza MN, McDougle CJ, Epperson CN. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series. J Clin Psychiatry. 1999 Aug; 60(8):524-7.
-
O'Malley GF, Seifert S, Heard K, Daly F, Dart RC. Olanzapine overdose mimicking opioid intoxication. Ann Emerg Med. 1999 Aug; 34(2):279-81.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|